Coldman A J, Goldie J H
Division of Epidemiology, Cancer Control Agency of British Columbia, Vancouver, Canada.
Semin Oncol. 1987 Dec;14(4 Suppl 4):29-33.
Using a somatic mutation theory for drug resistance, dose intense regimens are shown to be superior in increasing the likelihood of no doubly resistant cells and in curing the tumor. Consideration of this model suggests that dose intensity of early chemotherapy cycles should be calculated separately and correlated with treatment outcome.
根据抗药的体细胞突变理论,高剂量强度方案在增加无双重耐药细胞的可能性以及治愈肿瘤方面显示出优越性。对该模型的考量表明,早期化疗周期的剂量强度应单独计算,并与治疗结果相关联。